The CardioGENE lab test identifies inherited genetic markers in blood samples which drive pathways to prevent cardiovascular issues with prophylactic targeted treatment
AMPEL BioSolutions has announced the new CardioGENE lab test. (Credit: AMPEL BioSolutions)
AMPEL BioSolutions, a US-based precision medicine company, has unveiled the new CardioGENE lab test to predict heart diseases and provide decision support for prophylactic therapies for women with lupus.
The company said that the test identifies inherited genetic markers in blood samples that drive pathways, which can be targeted by drugs. CardioGENE will be able to serve as a decision-support biomarker test, said AMPEL BioSolutions.
According to the firm, the technique of connecting genetic predisposition to molecular pathways targeted by drugs could help healthcare providers to identify cardiovascular disease risk after a lupus diagnosis and choose suitable preventative treatments.
AMPEL BioSolutions co-founder, president, and chief scientific officer Amrie Grammer said: “CardioGENE marks a diversification of AMPEL’s portfolio into genetic testing, and we are extremely excited to share our results.
“We are confident that CardioGENE will make a difference in the lives of lupus patients, especially young women who disproportionately suffer from the disease’s cardiovascular impacts.”
The new test marks AMPEL BioSolutions’ expansion into genetic testing as a second platform technology along with existing work in the field of RNA analytics and machine learning.
CardioGENE will enable medical providers to use preventive tailored treatment to avert major cardiovascular events by identifying the DNA-driven pathways, the firm said.
AMPEL BioSolutions co-founder, CEO, and chief medical officer Peter Lipsky said: “This research not only contributes to our understanding of the genetic basis of the increased frequency of cardiovascular events in patients living with lupus, but also provides practical information on new molecular pathways contributing to atherosclerotic cardiovascular disease.
“We believe this work will usher in new approaches to ameliorate one of the leading causes of death in lupus patients.”
The test was developed in partnership with Wake Forest and was funded by a US Department of Defense (DoD) Impact Award, awarded in 2020.
AMPEL BioSolutions’ precision medicine test portfolio includes disease areas like systemic lupus erythematosus, scleroderma, psoriasis, lupus nephritis, atopic dermatitis, cardiovascular, fibromyalgia, Sjogren’s Syndrome, lung cancer, SARS-Cov2, and others.